Changes in cerebral blood flow after acetazolamide: an experimental study comparing near-infrared spectroscopy and SPECT
Version of Record online: 19 FEB 2009
© 2009 The Author(s). Journal compilation © 2009 EFNS
European Journal of Neurology
Volume 16, Issue 4, pages 461–467, April 2009
How to Cite
Schytz, H. W., Wienecke, T., Jensen, L. T., Selb, J., Boas, D. A. and Ashina, M. (2009), Changes in cerebral blood flow after acetazolamide: an experimental study comparing near-infrared spectroscopy and SPECT. European Journal of Neurology, 16: 461–467. doi: 10.1111/j.1468-1331.2008.02398.x
- Issue online: 19 MAR 2009
- Version of Record online: 19 FEB 2009
- Received 18 July 2008 Accepted 27 October 2008
- blood flow index;
- cerebral blood flow;
- indocyanine green;
- near-infrared spectroscopy;
- single photon emission computer tomography
Background and purpose: It is important to find a reliable and bedside method, which can estimate the cerebral blood flow (CBF) of patients in clinical settings. Estimation of CBF by calculating a blood flow index (BFI) using continuous wave near-infrared spectroscopy (CW-NIRS) and indocyanine green (ICG) as an iv tracer has been proposed to be a feasible and promising method. To validate if the BFI method can detect relative changes in CBF we compared data with the established method 133Xenon single photon emission computer tomography (133Xe-SPECT).
Methods: Ten healthy subjects were investigated before and after a bolus of acetazolamide. NIRS data were obtained using a multi source detector separation configuration in order to assess a corrected BFI (BFIcorr) value, which attempts to eliminate contamination of skin blood flow.
Results: Data obtained showed no significant correlation between CBF changes measured by 133Xe-SPECT and BFIcorr (0.133, P = 0.732). After acetazolamide, a 49% increase in CBF was detected using the 133Xe-SPECT method, whereas no changes in any ICG variables were observed after acetazolamide.
Conclusion: The study shows that it is not possible to obtain reliable BFI data, which reflect changes in CBF after acetazolamide infusion, using the CW-NIRS and ICG method.